LONDON, UK / ACCESSWIRE / July 13, 2020 / Hemogenyx Pharmaceuticals plc (LSE:HEMO)('Hemogenyx Pharmaceuticals' or the 'Company'), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the Board of Directors has agreed to grant options over a total of 6,200,626 ordinary shares of 1p each in the capital of the Company ('Share Options') to certain PDMRs and a member of the Scientific Advisory Board of the Company.
The details of the Share Options granted are set out below:
Following the grant of the Share Options, in aggregate there will be 36,753,702 ordinary shares of 1p each of the Company under option to directors, employees and members of the Scientific Advisory Board of the Company, representing 8.48% of the issued ordinary share capital of the Company.
Notification and public disclosure of transactions by persons discharging managerial responsibilities ('PDMR') and persons closely associated with them ('PCA'):
- Aggregated volume
Date of the transaction
Place of the transaction
Outside of a trading venue
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact email@example.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View source version on accesswire.com: